Status:

COMPLETED

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Lead Sponsor:

Menarini Group

Conditions:

Advanced or Metastatic Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatmen...

Detailed Description

This Phase Ib study will investigate the safety and anti-tumor activity of daily oral doses MEN1611 in combination with Trastuzumab with/without Fulvestrant in female and male patients affected by adv...

Eligibility Criteria

Inclusion

  • Main
  • Histologically confirmed invasive adenocarcinoma of the breast
  • Known HER2+ breast cancer
  • Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample
  • \> 2 lines of anti-HER2 based regimens with at least 1 regimen with trastuzumab
  • Radiological documented evidence of progressive disease
  • Life expectancy ≥ 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Main

Exclusion

  • Previous treatment with PI3K inhibitors
  • Brain metastases untreated, unless treated \> 4 weeks and only if clinically stable and not receiving corticosteroids
  • History of clinically significant bowel disease
  • ≥ grade 2 diarrhoea
  • History of significant, uncontrolled, or active cardiovascular disease
  • Any serious and/or unstable pre-existing psychiatric or neurologic illness or other conditions that could interfere with patient's safety
  • Not controlled diabetes mellitus (glycated haemoglobin \[HbA1c\] \>7%) and fasting plasma glucose \>126 mg/dL
  • Concurrent chronic treatment with steroids, as immunosuppressant, or another immunosuppressive agent

Key Trial Info

Start Date :

November 13 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 23 2024

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT03767335

Start Date

November 13 2018

End Date

February 23 2024

Last Update

June 26 2025

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Holy Cross Hospital Inc.

Fort Lauderdale, Florida, United States, 33308

2

Detroit Clinical Research Center

Farmington Hills, Michigan, United States, 48334

3

Washington University

St Louis, Missouri, United States, 63130

4

Cliniques Universitaires Saint-Luc

Brussels, Belgium

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer | DecenTrialz